Olema Pharmaceuticals, Inc.
NASDAQ:OLMABiotechnology
Healthcare
$7.06 -2.70%
-$0.26 today
- Market cap
- $618.50M
- Beta
- 2.00
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$1.80
52W Low $4.02High $36.26
Volume 1.18M
Average 1.27M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$178.70M
FY 2025 · Annual
Net Income
-$162.45M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 51.1M | 82.27M | 86.14M | 124.52M | 157.7M |
| Selling, General & Admin | 20.39M | 24.71M | 18.82M | 17.74M | 21M |
| Operating Expenses | 71.49M | 106.99M | 104.96M | 142.26M | 178.7M |
| Depreciation & Amortization | 163K | 357K | 377K | 393K | 490K |
| EBITDA | (70.93M) | (104.43M) | (96.28M) | (129.08M) | (161.96M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (71.49M) | (106.99M) | (104.96M) | (142.26M) | (178.7M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 442K | 2.23M | 8.32M | 12.68M | 16.22M |
| Interest Expense | — | 0 | — | 0 | 0 |
| Other Income / Expenses | 395K | 2.2M | 8.31M | 12.78M | 16.25M |
| Income Before Tax | (71.1M) | (104.79M) | (96.66M) | (129.47M) | (162.45M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (71.1M) | (104.79M) | (96.66M) | (129.47M) | (162.45M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.79) | (2.62) | (2.14) | (2.20) | (1.87) |
| EPS (Diluted) | (1.79) | (2.62) | (2.14) | (2.20) | (1.87) |
| 39.52M | 40M | 45.25M | 58.74M | 87.01M | |
| 39.52M | 40M | 45.25M | 58.74M | 87.01M |
OLMA Earnings Waterfall · TTM
NASDAQ:OLMA · Revenue to Net Income
Key Ratios
EPS$-2.03
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-6.7
P/S Ratio0.0
Analysis
$0 of revenue converted into -$185.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.03, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 12, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| SC 13D/A | SC 13D/A filing | Oct 16, 2026 | |
| 8-K | Current report | Oct 15, 2026 |
How much revenue does OLMA generate?
Olema Pharmaceuticals, Inc. (OLMA) reported $0.00 of revenue in fiscal 2025.
Is OLMA profitable?
Olema Pharmaceuticals, Inc. (OLMA) reported -$162.45M of net income.
Continue the stock analysis
Jump to another research area for this company.